Calcium-regulating hormone
Salmon Calcitonin
The Miacalcin injection label gives salmon calcitonin's terminal half-life as 59 to 64 minutes after subcutaneous injection; the app lists 1.5 hours.1
Salmon Calcitonin after one dose: 50% at ~1.5 h, 25% at 3 h, 12.5% at 4.5 h.
Drawn from the half-life in the app's model, ~1.5 h. The model's figures
- Compound
- Salmon Calcitonin
- Symbol
- SCT
- Family
- Metabolic and mitochondrial peptides
- Parts
- 14
- References
- 9
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Salmon calcitonin is a 32-amino-acid polypeptide hormone; the Miacalcin injection label describes its product as a synthetic polypeptide in the same linear sequence found in calcitonin of salmon origin.1 The Miacalcin injection label lists three indications: symptomatic Paget's disease of bone when alternative treatments are not suitable, hypercalcemia, and postmenopausal osteoporosis when alternative treatments are not suitable.1 A US label for a nasal solution lists only postmenopausal osteoporosis, in women more than 5 years postmenopause when alternative treatments are not suitable, and carries the same fracture statement.2 Both US labels give 1975 as the initial approval year.1,2 The app lists the subcutaneous route only, so its figures are set against the injection label below, with the nasal label shown where it differs. The app grades the evidence as strong; that grade is the app's own and is not a conclusion of the sources, which include a label statement that fracture reduction has not been demonstrated.1
How it works
Sources in this part
The Miacalcin label calls calcitonin salmon a calcitonin receptor agonist that acts primarily on bone, with direct renal effects and actions on the gastrointestinal tract also recognized.1 On bone, the label describes "a marked transient inhibition of the ongoing bone resorptive process" after single injections and "a persistent, smaller decrease" with prolonged use, associated histologically with fewer osteoclasts.1 On the kidney, studies with injectable calcitonin salmon show increased excretion of filtered phosphate, calcium and sodium through decreased tubular reabsorption.1 In healthy adults, who have a relatively low rate of bone resorption, the label reports serum calcium decreases "within the limits of the normal range", with more pronounced decreases in healthy children and in patients whose bone resorption is more rapid.1 Against calcitonins of mammalian origin, the label states that the salmon form "appears to have actions essentially identical" but that "its potency per mg is greater and it has a longer duration of action".1 The nasal label carries the same wording, and neither label states a numerical multiple for the greater potency.2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~1.5 h
- Bioavailability
- 70%
- Typical dose
- 100–200 IU/day
- Route
- SubQ
- Time to peak
- ~1 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the labels report.
| Parameter | App's figure | Reported on the labels |
|---|---|---|
| Half-life | ~1.5 h | Terminal half-life approximately 58 minutes after intramuscular and 59 to 64 minutes after subcutaneous injection (Miacalcin injection label); around 18 minutes for the nasal solution (nasal label)1,2 |
| Bioavailability | 70% | Absolute bioavailability approximately 66% after intramuscular and 71% after subcutaneous injection (injection label); 3% to 5% relative to intramuscular administration for the nasal solution in healthy volunteers (nasal label)1,2 |
| Time to peak | ~1 h | Peak plasma levels reached in approximately 23 minutes after subcutaneous administration (injection label); mean Tmax of about 13 minutes for the nasal solution (nasal label)1,2 |
| Volume of distribution | Not listed | Apparent volume of distribution 0.15 to 0.3 L/kg (injection label)1 |
| Duration | ~10 h | No single-dose duration figure on the labels; in hypercalcemia trials, serum calcium fell within 1 to 2 hours, the peak effect occurred within 24 to 48 hours of injection, and dosing every 12 hours maintained a hypocalcemic effect for approximately 5 to 8 days (injection label)1 |
The app's half-life of 1.5 hours is longer than the labelled subcutaneous terminal half-life of 59 to 64 minutes, and the app's time to peak of about 1 hour is longer than the labelled approximately 23 minutes.1 The app's bioavailability of 70% sits between the labelled intramuscular and subcutaneous figures of 66% and 71%.1 No other pharmacokinetic source for the app's figures was identified: a search of PubMed for subcutaneous or intramuscular pharmacokinetics in healthy volunteers returned no records.
The level chart uses the app's figures and the dosing intervals that the injection label gives.
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: once daily (Paget's disease and osteoporosis dosing on the label)1, every 12 hours (starting hypercalcemia dosing on the label)1.
An illustration from a pharmacokinetic model using a half-life of 1.5 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Injection label, Paget's disease studies (undated)1 | Open-label trials with historical controls1 | Patients with moderate to severe Paget's disease (polyostotic involvement, elevated alkaline phosphatase and urinary hydroxyproline); number not stated1 | Several months to two years1 | Biochemical abnormalities improved by more than 30% in about 2/3 of patients studied, with bone pain improved in a similar fraction; hearing loss improved in 4 of 29 patients studied by audiometry1 |
| Injection label, hypercalcemia trials (undated)1 | Four open-label trials, with each patient's pre-therapy serum calcium as the control1 | 53 patients with carcinoma, multiple myeloma or primary hyperparathyroidism, given calcitonin salmon when other measures had been unsuccessful or unsuitable1 | Every 12 hours, evaluated for approximately 5 to 8 days in most patients1 | Average reduction of 8-hour post-injection serum calcium of approximately 9% (2 to 3 mg/dL); lesser response in primary hyperparathyroidism1 |
| Injection label, two osteoporosis studies (undated)1 | Two randomized, open-label, 2-year studies; primary endpoint total body calcium1 | Postmenopausal women aged 50 to 74; 34 on calcitonin salmon and 35 controls across the two studies1 | 100 International Units daily, subcutaneous or intramuscular, at bedtime, against control, with calcium and vitamin D for all; 2 years1 | Total body calcium rose at 1 year and trended down, still above baseline, at 2 years; new vertebral compression fractures were 6 against 5 in year 1 and 7 in each group in year 21 |
| Rijnstate Hospital, pilot registry entry NCT00688077 (registered 2008)3 | Non-randomised, single-masked, placebo-controlled crossover3 | Healthy men aged 20 to 55; the description states twelve subjects, while the enrollment field gives a count of 49 (actual)3 | Single subcutaneous injection of calcitonin 200 IU/ml against saline placebo; 8-hour sampling3 | Registry status COMPLETED; the entry's "Has Results" field reads "undefined", so no result is reported here. The registry entry names the intervention as calcitonin and does not state that it is salmon calcitonin.3 |
| Chesnut and colleagues, PROOF, American Journal of Medicine 20004 | 5-year, double-blind, randomized, placebo-controlled; nasal spray, not injection4 | 1,255 postmenopausal women with established osteoporosis4 | Nasal spray 100, 200 or 400 IU daily or placebo, with calcium 1,000 mg and vitamin D 400 IU; 5 years4 | New vertebral fractures 51 of 287 on 200 IU against 70 of 270 on placebo (RR 0.67, 95% CI 0.47 to 0.97, P = 0.03); the 100 IU and 400 IU groups were not significantly different from placebo4 |
| Binkley and colleagues, ORACAL, Journal of Bone and Mineral Research 20125 | Randomized, double-blind, double-dummy, active- and placebo-controlled phase 35 | 565 postmenopausal women aged 46 to 86 (mean 66.5)5 | Oral recombinant salmon calcitonin 0.2 mg/d, synthetic salmon calcitonin nasal spray 200 IU/d, or placebo; 48 weeks5 | Lumbar spine BMD change 1.5% oral, 0.78% nasal, 0.5% placebo; the nasal spray did not differ from placebo; about 80% in each group had an adverse event5 |
| Overman and colleagues, Annals of Pharmacotherapy 20136 | Review of randomized trials comparing nasal or oral salmon calcitonin with placebo6 | 18 studies; searches of MEDLINE, MEDLINE/OVID and EMBASE, January 1973 to September 20136 | Nasal or oral formulations, varying lengths6 | Percentage with malignancy greater in the salmon calcitonin arm in 15 of 18 studies; most studies had poor-quality methods to assess new cancer cases6 |
| Sun and colleagues, Journal of Clinical Endocrinology and Metabolism 20147 | Population-based nested case-control study of the Taiwan National Health Insurance Research Database7 | 28 222 patients with osteoporosis diagnosed 2000 to 2011; 1925 with cancer matched to controls7 | Nasal spray use taken from the Taiwan National Health Insurance Research Database; monthly dosage analysed7 | In women, liver cancer OR 1.94 (95% CI 1.23 to 3.05) and breast cancer OR 0.35 (95% CI 0.15 to 0.80)7 |
Apart from the two small randomized open-label studies (34 on calcitonin salmon and 35 controls combined) and the prematurely discontinued controlled study described on the injection label, no controlled trial of subcutaneous or intramuscular salmon calcitonin with fracture or mortality outcomes was identified in the searches run for this compound, which were PubMed searches on cancer risk, pharmacokinetics, Paget's disease, osteoporosis and hypercalcemia, and a ClinicalTrials.gov search on "calcitonin".1
Deeper analysis: the injection label's trials
The Miacalcin label is a manufacturer document, and it states that its Paget's disease evidence came from open-label trials "with historical controls" and its hypercalcemia evidence from open-label trials that used each patient's pre-therapy calcium as the control.1 The label does not name the funders or the authors of those trials; it identifies Mylan Institutional LLC as the labeler and says Miacalcin is a registered trademark of Novartis AG, licensed to the Viatris Companies.1 For osteoporosis, the label says the evidence of efficacy "is based on increases in total body calcium observed in clinical trials" and that "Fracture reduction efficacy has not been demonstrated".1 The label adds that "A controlled study, which was prematurely discontinued, failed to demonstrate any benefit of calcitonin salmon on fracture rate", and that no adequate controlled trials have examined vertebral bone mineral density beyond 1 year.1
Deeper analysis: PROOF
Chesnut and colleagues reported PROOF in the American Journal of Medicine in 2000; the first author is listed at the University of Washington, Seattle.4 It was a 5-year, double-blind, randomized, placebo-controlled study of a nasal spray, not an injection, whose primary endpoint was the risk of new vertebral fractures in the 200 IU group against placebo.4 Of 1,255 women randomised, 1,108 had at least one follow-up radiograph, 783 completed 3 years and 511 completed 5 years.4 The authors report that the 200 IU dose "significantly reduced the risk of new vertebral fractures by 33% compared with placebo", and a 36% reduction (RR 0.64, 95% CI 0.43 to 0.96, P = 0.03) in the 817 women with one to five prevalent vertebral fractures at enrollment.4 The 100 IU result (RR 0.85, 95% CI 0.60 to 1.21) and the 400 IU result (RR 0.84, 95% CI 0.59 to 1.18) were not significantly different from placebo.4 The record also reports that lumbar spine bone mineral density increased significantly from baseline in all active treatment groups (P<0.01).4 The PubMed record carries no statement of the authors' limitations, no funding statement, no author disclosures and no adverse event or discontinuation figures, so none are given here.
Deeper analysis: ORACAL
Binkley and colleagues reported ORACAL in the Journal of Bone and Mineral Research in 2012; the first author is listed at the University of Wisconsin, Madison.5 The trial tested oral recombinant salmon calcitonin tablets, a different product from the injected form, against a nasal spray of synthetic salmon calcitonin and placebo for 48 weeks.5 Lumbar spine bone mineral density rose by 1.5% on oral recombinant calcitonin, 0.78% on the nasal spray and 0.5% on placebo, and the authors state that the nasal group "did not differ from placebo".5 The authors report that "Approximately 80% of subjects in each treatment group experienced an adverse event, the majority of which were mild or moderate in intensity", that gastrointestinal events affected nearly one-half of women in every group and were the principal reason for premature withdrawals, and that less than 10% had a serious adverse event with no deaths.5 The record also reports greater improvements in trochanteric and total proximal femur BMD with oral recombinant calcitonin than with the nasal spray, and greater reductions in bone resorption markers with the oral product than with the nasal spray or placebo.5 The PubMed record gives no sponsor, funding statement or authors' limitations, so the sponsor and any author ties to it are not stated here. The record lists the publication type "Research Support, Non-U.S. Gov't" for ORACAL without naming a funder.5 The oral product's result is not a result for injected salmon calcitonin.
Deeper analysis: the cancer-risk signal
The US injection label summarises a meta-analysis of 21 randomized, controlled trials of calcitonin salmon given as nasal spray or investigational oral formulations, with durations of 6 months to 5 years and 10883 patients (6151 treated, 4732 on placebo).1 Malignancies were reported in 254 of 6151 (4.1%) on calcitonin salmon and 137 of 4732 (2.9%) on placebo; among the 18 nasal-spray-only trials the figures were 122 of 2712 (4.5%) and 30 of 1309 (2.3%).1 The label states that the result "was heavily influenced by a single large 5-year trial", with an observed risk difference of 3.4% (95% CI 0.4% to 6.5%), that a mechanism "has not been identified", and that "a definitive causal relationship" cannot be established from the meta-analysis.1 The European Medicines Agency's committee reported on 20 July 2012 that in long-term clinical trials the risk of developing cancer was 0.7% to 2.4% higher with calcitonin-containing medicines than with placebo, with the higher rates in intranasal trials.8 Overman and colleagues, in the Annals of Pharmacotherapy in 2013, wrote that current evidence "may suggest an association" based on studies with poor-quality cancer assessment methods, and that, given the lack of demonstrated fracture efficacy, advised clinicians to consider discontinuing use for osteoporosis.6 Sun and colleagues, in the Journal of Clinical Endocrinology and Metabolism in 2014, reported in Taiwanese women with osteoporosis a higher risk of liver cancer (OR 1.94, 95% CI 1.23 to 3.05) and a lower risk of breast cancer (OR 0.35, 95% CI 0.15 to 0.80) with nasal spray use, with the liver cancer association limited to higher-dose users.7 They conclude that their data "do not completely support the decision to discontinue use of CNS in osteoporosis patients".7 The PubMed records for Overman and colleagues and for Sun and colleagues do not give funding statements or author ties to a sponsor; the Sun record lists the publication type "Research Support, Non-U.S. Gov't".7 Rat studies summarised on the label showed more pituitary adenomas after subcutaneous synthetic calcitonin salmon, and mice dosed for two years at up to 800 International Units/kg/day showed no carcinogenicity potential; the label calls the significance of the rat finding to humans unknown.1
Doses reported in studies and on labels
The app lists 100 to 200 IU per day subcutaneously; the injection label gives 100 USP Units daily for Paget's disease and for postmenopausal osteoporosis, and weight-based dosing for hypercalcemia.
| Source | Setting | Dose | Route, duration and comparator |
|---|---|---|---|
| Miacalcin injection label1 | Symptomatic Paget's disease of bone | 100 USP Units per day | Subcutaneous or intramuscular |
| Miacalcin injection label1 | Hypercalcemia | Start with 4 USP Units/kg body weight every 12 hours; increase to 8 USP Units/kg every 12 hours if no improvement in 1 to 2 days; further to 8 USP Units/kg every 6 hours if no improvement after 2 more days | Subcutaneous or intramuscular |
| Miacalcin injection label1 | Postmenopausal osteoporosis, women more than 5 years postmenopause | 100 USP Units per day; the minimum effective dose for preventing vertebral bone mineral density loss has not been established | Subcutaneous or intramuscular |
| Nasal solution label2 | Postmenopausal osteoporosis | One spray (200 International Units) per day, alternating nostrils daily | Intranasal only |
| Chesnut and colleagues, PROOF4 | Established osteoporosis, n = 1,255 | 100, 200 or 400 IU per day against placebo | Nasal spray, up to 5 years |
| Binkley and colleagues, ORACAL5 | Postmenopausal osteoporosis, n = 565 | Oral recombinant salmon calcitonin 0.2 mg/d, or synthetic salmon calcitonin nasal spray 200 IU/d, against placebo | Oral or nasal, 48 weeks |
| Registry entry NCT006880773 | Healthy men, crossover pilot | Calcitonin 200 IU/ml, single injection, against saline placebo | Subcutaneous, one dose |
Side effects reported
Sources in this part
For the injection, the label lists nausea with or without vomiting in about 10% of patients, local inflammatory reactions at the injection site in about 10%, and flushing of the face or hands in about 2% to 5%.1 It states that nausea is most evident when treatment starts and tends to decrease or disappear with continued administration.1 The label lists serious hypersensitivity reactions, including bronchospasm, swelling of the tongue or throat, anaphylactic shock and death due to anaphylaxis.1 It lists hypocalcemia with tetany and seizure activity.1 For the nasal solution, the label lists rhinitis (12%), epistaxis (4%) and sinusitis (2%) as the most commonly reported nasal adverse reactions in postmenopausal patients.2 On antibodies, the injection label reports circulating antibodies after 2 to 18 months of treatment in about one-half of patients with Paget's disease in whom antibody studies were done, and says that patients with high titers "usually will have a loss of response to treatment".1 The label states that safety and effectiveness in pediatric patients have not been established.1
Bloodwork and markers
Sources in this part
The app lists calcium as the marker to monitor.1 The injection label states that hypocalcemia "must be corrected before initiating therapy" and names vitamin D deficiency as another disorder of mineral metabolism to be effectively treated.1 For patients at risk of hypocalcemia, the label states that serum calcium and symptoms are monitored during the first several administrations, with parenteral calcium available.1 In hypercalcemia trials of 53 patients, the average reduction of 8-hour post-injection serum calcium was approximately 9% (2 to 3 mg/dL), with greater reductions in patients with higher starting values.1 The label lists periodic examination of urine sediment as something to consider.1 In PROOF, serum C-telopeptide, a bone resorption marker, was suppressed by 12% on 200 IU and 14% on 400 IU of nasal spray against placebo.4
Regulatory and anti-doping status
In the United States, the injection label lists Paget's disease, hypercalcemia and postmenopausal osteoporosis, and its limitations of use say that, because of the possible association between malignancy and calcitonin salmon use, the need for continued therapy is to be re-evaluated on a periodic basis.1 In the European Union, the Committee for Medicinal Products for Human Use recommended on 20 July 2012 that calcitonin-containing medicines be used only for short-term treatment because of evidence that long-term use is associated with an increased risk of cancer.8 It recommended that the nasal spray be withdrawn, concluding that the benefits of calcitonin-containing medicines did not outweigh their risks in postmenopausal osteoporosis, taking into account their limited efficacy in reducing the risk of vertebral fractures.8 It recommended that calcitonin be available only as a solution for injection and infusion and be used only for prevention of acute bone loss due to sudden immobilisation, Paget's disease in patients who do not respond to alternative treatments or for whom such treatments are not suitable, and hypercalcaemia caused by cancer.8 For Paget's disease, it stated that treatment is normally limited to 3 months, extendable to 6 months in exceptional circumstances.8 The press release states the opinion was being forwarded to the European Commission for a decision; the final decision is not covered by the sources read.8 The word calcitonin does not appear in the text of the World Anti-Doping Agency's 2026 Prohibited List, including its S2 section on peptide hormones, growth factors, related substances and mimetics.9
Storage and handling
Sources in this part
The injection label states storage in a refrigerator between 2° and 8°C (36° to 46°F) and protection from freezing.1 The nasal label states that an unopened bottle is stored in a refrigerator between 2°C and 8°C, and that a bottle in use is kept upright at room temperature between 20°C and 25°C for up to 35 days.2
What is not known
Sources in this part
Fracture reduction with salmon calcitonin has not been demonstrated according to both US labels.1,2 Whether long-term subcutaneous, intramuscular or intravenous use carries the cancer signal seen in the nasal and oral trials is not established, because the label says those routes were not investigated in the meta-analysis.1 The minimum effective dose for preventing vertebral bone mineral density loss has not been established, and no adequate controlled trials have examined vertebral density beyond 1 year of injection.1 The labels give no numerical multiple for the greater potency of the salmon form over mammalian calcitonins, and none of the texts read gives a basis for the app's note of a 40 to 50 times difference. The labelled terminal half-life and time to peak are shorter than the app's figures, and none of the texts read accounts for the difference.
Frequently asked questions
What is the half-life of salmon calcitonin?
How long does salmon calcitonin take to reach its peak level?
The injection label gives peak plasma levels in approximately 23 minutes after subcutaneous administration, and the app lists about 1 hour.1
What is the bioavailability of salmon calcitonin?
The injection label gives absolute bioavailability of approximately 66% after intramuscular and 71% after subcutaneous injection, and the app lists 70%.1
Is salmon calcitonin banned by WADA?
The word calcitonin does not appear in the text of the 2026 WADA Prohibited List that was searched.9
What is salmon calcitonin approved for in the United States?
The Miacalcin injection label lists symptomatic Paget's disease of bone and postmenopausal osteoporosis when alternative treatments are not suitable, and hypercalcemia.1 The nasal solution label lists postmenopausal osteoporosis in women more than 5 years postmenopause when alternative treatments are not suitable.2
Is salmon calcitonin linked to cancer?
A meta-analysis of 21 randomized trials of nasal spray or investigational oral calcitonin salmon, summarised on the US label, reported malignancies in 4.1% of treated patients and 2.9% of placebo patients.1 The label states a definitive causal relationship cannot be established from that meta-analysis, and that an increased risk cannot be excluded for the subcutaneous, intramuscular or intravenous routes because they were not investigated in it.1
Was calcitonin nasal spray withdrawn in Europe?
The European Medicines Agency's committee recommended on 20 July 2012 that the nasal spray be withdrawn, after concluding that the benefits of calcitonin-containing medicines did not outweigh their risks in postmenopausal osteoporosis, the only use of the nasal spray.8
What are the common side effects of salmon calcitonin injection?
The injection label lists nausea with or without vomiting in about 10% of patients, local inflammatory reactions at the injection site in about 10%, and flushing of the face or hands in about 2% to 5%.1
More in Metabolic and mitochondrial peptides
References
- Mylan Institutional LLC. Miacalcin (calcitonin salmon) injection, for subcutaneous or intramuscular use. US prescribing information, DailyMed record version 9. DailyMed label (injection)
- Par Health USA, LLC. Calcitonin salmon nasal solution. US prescribing information, DailyMed record version 22, 2026. DailyMed label (nasal solution)
- Rijnstate Hospital. FGF-23 Suppressibility by Calcitonin. ClinicalTrials.gov NCT00688077. NCT00688077
- Chesnut CH, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000. PMID 10996576
- Binkley N, et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res 2012. PMID 22437792
- Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associated cancer risk. Ann Pharmacother 2013. PMID 24259626
- Sun LM, et al. Calcitonin nasal spray and increased cancer risk: a population-based nested case-control study. J Clin Endocrinol Metab 2014. PMID 25144633
- European Medicines Agency. European Medicines Agency recommends limiting long-term use of calcitonin medicines. Press release EMA/CHMP/483874/2012, 20 July 2012. EMA press release
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list